Quantum Genesis AI Corp. (OTC: QGAI) has issued a statement addressing the Caveat Emptor designation placed on its securities by OTC Markets Group, Inc. on February 12, 2026. The company, which focuses on artificial intelligence, computational modeling, and scientific innovation, expressed its commitment to understanding the basis for the designation and taking appropriate steps to resolve the matter.
Since the designation was applied, Quantum Genesis AI has made several attempts to communicate with OTC Markets to better understand the reason for the designation and determine necessary actions. OTC Markets indicated that the designation relates to a “public interest concern,” but the company has requested additional clarification. Quantum Genesis AI intends to continue cooperating with OTC Markets to address the issue.
OTC Markets recently informed the company that it may formally request a review of the Caveat Emptor designation beginning March 13, 2026. Quantum Genesis AI plans to engage with OTC Markets at the earliest opportunity to initiate that review process. Naveen Kulkarni, Chief Executive Officer of Quantum Genesis AI Corp., stated, “We take this matter seriously and are committed to working constructively with OTC Markets to better understand the basis for the designation. Our objective is to obtain clarity regarding the matter and to take any appropriate steps necessary as we move through the review process.”
The Caveat Emptor designation is significant because it alerts investors that there may be a public interest concern associated with the company’s stock, potentially affecting investor confidence and the stock’s liquidity. The company’s response indicates a proactive approach to addressing regulatory concerns, which could mitigate negative impacts on its reputation and market performance. Quantum Genesis AI remains committed to maintaining transparency with its shareholders and the broader investment community, and it intends to provide updates as additional information becomes available.
For more information, visit the company’s website at www.qgaicorp.com and its profile on OTC Markets at www.otcmarkets.com/stock/QGAI.
